- Active not recruitingPHASE3
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
This study looks at new ways to treat childhood acute lymphoblastic leukemia (ALL). It explores how to choose the right treatment strength for each child and tests a new way to give a common chemotherapy drug called pegaspargase.
For: Acute Lymphoblastic Leukemia, PediatricUnited States · Canada - RecruitingPHASE3
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
This study looks at new ways to treat childhood leukaemia (ALL) in children and teenagers. It aims to make treatments kinder and more effective by using smart medicines (immunotherapy) and targeting specific cancer features, reducing the need for harsh chemotherapy.
For: Acute Lymphoblastic Leukemia, PediatricAustralia · Austria · Czechia - Active not recruitingPHASE1, PHASE2
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
This study looks at new drug combinations for babies with a type of blood cancer called acute lymphoblastic leukaemia (ALL). It explores how well new drugs, bortezomib and vorinostat, work with standard treatments and checks for any side effects, aiming to improve treatment outcomes for these infants.
For: Acute Lymphoblastic LeukemiaUnited States · Canada - AuthorisedTherapeutic confirmatory (Phase III)
CAALL-F01: a French protocol for the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents
This study looks at a new way to treat a type of blood cancer called acute lymphoblastic leukemia (ALL) in children and teenagers (aged 12 months to under 18 years). It’s testing different ways of giving a medicine called pegaspargase to see how well it works and if it causes side effects.
For: This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic · characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the · tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newlyFrance